MRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients.

ABSTRACT:

Background

Cell-mediated immunity may provide durable protection against severe COVID-19, including among solid organ transplant recipients (SOTRs). This exploratory analysis in the open-label phase 3b trial evaluated cell-mediated immunity of mRNA-1273 in a subset of participants (59 kidney and 33 liver SOTRs; 12 immunocompetent participants).

Methods

In Part A, SOTRs received three 100-µg doses of mRNA-1273; immunocompetent participants received two doses. In Part B, an additional 100-µg dose was offered ≥4 months after the primary series. SARS-CoV-2 spike (S) protein-specific T-cell responses were measured by intracellular cytokine staining and polyfunctionality analyses.

Results

The primary series and additional dose of mRNA-1273 induced S protein-specific CD4

SUBMITTER: Girard B 

PROVIDER: S-EPMC12004975 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature